Cost and outcomes associated with rivaroxaban vs enoxaparin for the prevention of postsurgical venous thromboembolism from a US payer’s perspective

References

• Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines. 8th edn. Chest 2008;133(6 Suppl):381S‐453S
   Google Scholar
• Sullivan SD, Kahn SR, Davidson BL, et al. Measuring the outcomes and pharmacoeconomic consequences of venous thromboembolism prophylaxis in major orthopaedic surgery. PharmacoEconomics 2003;21:477‐96
   PubMed Web of Science ®Google Scholar
• Agency for Healthcare Research and Quality. Healthcare Cost & Utilization Project (HCUP). United States Department of Health & Human Services 2009. Available at: http://www.ahrq.gov/data/hcup. Accessed September 2, 2011
   Google Scholar
• XARELTO full prescribing information. Titusville, NJ: Janssen Pharmaceuticals, Inc, 2011
   Google Scholar
• Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008;358:2765‐75
   PubMed Web of Science ®Google Scholar
• Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008;372:31‐9
   PubMed Web of Science ®Google Scholar
• Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008;358:2776‐86
   PubMed Web of Science ®Google Scholar
• Turpie AG, Lassen MR, Davidson BL, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009;373:1673‐80
   PubMed Web of Science ®Google Scholar
• Baser O, Supina D, Sengupta N, et al. Impact of postoperative venous thromboembolism on Medicare recipients undergoing total hip replacement or total knee replacement surgery. Am J Health Syst Pharm 2010;67:1438‐45
   PubMedGoogle Scholar
• Sullivan SD, Davidson BL, Kahn SR, et al. A cost-effectiveness analysis of fondaparinux sodium compared with enoxaparin sodium as prophylaxis against venous thromboembolism: use in patients undergoing major orthopaedic surgery. PharmacoEconomics 2004;2:605‐20
   Google Scholar
• Sullivan SD, Kwong L, Nutescu E. Cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against venous thromboembolism in patients undergoing hip fracture surgery. Value Health 2009;9:68‐76
   Google Scholar
• Bishop B, Wilson AG, Post D, et al. A pilot study of home treatment of deep vein thrombosis with subcutaneous once-daily enoxaparin plus warfarin. J Manag Care Pharm 2006;12:70‐5
   PubMedGoogle Scholar
• Botteman MF, Caprini J, Stephens JM, et al. Results of an economic model to assess the cost-effectiveness of enoxaparin, a low-molecular-weight heparin, versus warfarin for the prophylaxis of deep vein thrombosis and associated long-term complications in total hip replacement surgery in the United States. Clin Ther 2002;24:1960‐86
   PubMed Web of Science ®Google Scholar
• Spruill WJ, Wade WE, Leslie RB. Cost analysis of fondaparinux versus enoxaparin as venous thromboembolism prophylaxis in elective hip replacement surgery. Blood Coagul Fibrinolysis 2004;5:539‐43
   Google Scholar
• Friedman RJ, Gallus AS, Cushner FD, et al. Physician compliance with guidelines for deep-vein thrombosis prevention in total hip and knee arthroplasty. Curr Med Res Opin 2008;24:87‐97
   PubMed Web of Science ®Google Scholar
• Quinlan DJ, Eikelboom JW, Dahl OE, et al. Association between asymptomatic deep vein thrombosis detected by venography and symptomatic venous thromboembolism in patients undergoing elective hip or knee surgery. J Thromb Haemost 2007;5:1438‐43
   PubMed Web of Science ®Google Scholar
• White RH, Romano PS, Zhou H, et al. Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch Intern Med 1998;158:1525‐31
   PubMed Web of Science ®Google Scholar
• Bureau of Labor Statistics UDoL. Consumer Price Index. All urban consumers. Available at: http://www.bls.gov/news.release/cpi.t01.htm. Accessed September 2, 2011
   Google Scholar
• McGarry LJ, Thompson D, Weinstein MC, et al. Cost effectiveness of thromboprophylaxis with a low-molecular-weight heparin versus unfractionated heparin in acutely ill medical inpatients. Am J Manag Care 2004;10:632‐42
   PubMed Web of Science ®Google Scholar
• DRG Expert: A Comprehensive Guidebook to the DRG Classification System. 24th edition. Salt Lake City, UT: Ingenix; 2008
   Google Scholar
• Spyropoulos AC, Lin J. Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations. J Manag Care Pharm 2007;13:475‐86
   PubMed Web of Science ®Google Scholar
• Arias E. United States Life tables, 2006. Available at http://www.cdc.gov/nchs/data/nvsr/nvsr58/nvsr58_21.pdf. Accessed September 2, 2011
   Google Scholar
• Goldhaber SZ, Tapson VF. A prospective registry of 5,451 patients with ultrasound-confirmed deep vein thrombosis. Am J Cardiol 2004;93:259‐62
   PubMed Web of Science ®Google Scholar
• Briggs A, Claxton K, Sculpher M. Decision modelling for health economic evaluation. Oxford: Oxford University Press, 2006, pp. 256
   Google Scholar
• AnalySource Online. Available at: http://www.analysource.com [Last accessed 2 September, 2011]
   Google Scholar
• Centers for Medicare and Medicaid Services. Medicare DRG Payments. Available at: https://www.cms.gov/AcuteInpatientPPS/FFD/list.asp. [Last accessed 2 September, 2011]
   Google Scholar
• Beebe M, Dalton J, Espronceda M. Current Procedural Terminology (CPT): 2008 Professional edition. Chicago: American Medical Association, 2008
   Google Scholar
• Thompson Healthcare. Red book: pharmacy’s fundamental reference. Montvale, NJ: Thompson Healthcare, 2008
   Google Scholar
• Centers for Medicare and Medicaid Services. 2011. Clinical lab fee schedule, Health and Human Services. Available at: https://www.cms.gov/ClinicalLabFeeSched. Accessed September 2, 2011
   Google Scholar
• Gould MK, Dembitzer AD, Sanders GD, et al. Low molecular weight heparins compared with unfractionated heparin for treatment of acute deep vein thrombosis. Ann Intern Med 1999;130:789‐99
   PubMedGoogle Scholar
• Oster G, Tuden RL, Colditz GA. A cost-effectiveness analysis of prophylaxis against deep-vein thrombosis in major orthopedic surgery. JAMA 1987;257:203‐8
   PubMed Web of Science ®Google Scholar
• Douketis JD, Eikelboom JW, Quinlan DJ, et al. Short-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of prospective studies investigating symptomatic outcomes. Arch Intern Med 2002;162:1465‐71
   PubMed Web of Science ®Google Scholar
• Carter CJ. New developments in acute anticoagulation therapy: what improvements over traditional heparin are on the horizon? Postgrad Med 1996;99:129‐36
   PubMed Web of Science ®Google Scholar